default author photo

Jordan Berlin

Vanderbilt University - Division of Hematology and Oncology

SCHOLARLY PAPERS

2

DOWNLOADS

96

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Phase 2 Study of Elraglusib (9-Ing-41), a Glycogen Synthase Kinase-3β Inhibitor, in Combination with Gemcitabine Plus Nab-Paclitaxel in Patients with Previously Untreated Metastatic Pancreatic Cancer

Number of pages: 40 Posted: 30 May 2024
affiliation not provided to SSRN, University of Kansas - Cancer Center, affiliation not provided to SSRN, INCLIVA Biomedical Research Institute, University of Michigan at Ann Arbor, Fred Hutchinson Cancer Research Center - Clinical Research Division, Vanderbilt University - Vanderbilt-Ingram Cancer Center, Netherlands Cancer Institute, Northwestern University - Northwestern Memorial Hospital, Brown University, Emory University - School of Medicine, INCLIVA Biomedical Research Institute, Vanderbilt University - Division of Hematology and Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Brown University
Downloads 64 (924,743)

Abstract:

Loading...

GSK-3β Inhibitor, elraglusib (9-ING-41), pancreatic cancer, combination, previously untreated

2.

Efficacy and Toxicity of Anti-Vascular Endothelial Growth Receptor Tyrosine Kinase Inhibitors in Patients with Neuroendocrine Tumors – A Systematic Review and Meta-Analysis

Number of pages: 9 Posted: 20 Sep 2022
Vanderbilt University - Division of Hematology and Oncology, Vanderbilt University - Department of Biostatistics, Vanderbilt University - Division of Hematology and Oncology, Vanderbilt University - Division of Hematology and Oncology, University of California, San Francisco (UCSF) - Department of Medicine, H. Lee Moffit Cancer Center, Harvard University - Dana-Farber Cancer Institute, Vanderbilt University, Vanderbilt University - Division of Hematology and Oncology, Vanderbilt University - Division of Hematology and Oncology and University of Texas at Houston - MD Anderson Cancer Center
Downloads 32 (1,290,922)

Abstract:

Loading...

Anti-vascular endothelial growth factor, receptor tyrosine kinase inhibitors, neuroendocrine tumors, toxicity, objective response rate, progression-free survival, systematic review & meta-analysis